Our CMO, Dr. Charles Bridges, joined the Empowered Patient Podcast to discuss challenges diagnosing #PulmonaryHypertension and how our non-invasive technology is enabling rapid, early detection of heart conditions. Listen here: bit.ly/3XjH3Mb

#AI & machine learning are revolutionizing healthcare—enhancing diagnostics & expanding access to underserved communities. CorVista shares insights on these non-invasive, data-driven solutions in this installation of Scrip, Citeline Commercial Scrip Asks 2025: bit.ly/3PWQjBR

Our IND application for the evaluation of our Cell Pouch bio-hybrid organ in combination with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease has been cleared by the U.S. FDA. Read more: bit.ly/4kqfv1s

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease. $CLN fiercebiotech.com/biotech/celons…

🎧 Conquering Complex Diseases Affecting Billions with Precision Medicine Uli Stilz, PhD, Novo Nordisk VP and Bio Innovation Hub founder, outlines a genetic medicine roadmap for treating multifactorial diseases like diabetes Novo Nordisk US Jonathan D. Grinstein, PhD hubs.li/Q039rjVr0

In a recent episode of the Diabetech podcast, our CEO, Jonathan Rigby, talks about his experience living with T1D and how the Sernova team is working to advance our Cell Pouch bio-hybrid organ through the clinic. Watch the interview here: bit.ly/3F8McAw

Woody Bryan Revolo Biotherapeutics, discusses eosinophilic esophagitis, how the company’s experimental therapy restores homeostasis to the immune system, and how people who were exposed to tuberculosis pointed the way toward the experimental therapy. thebioreport.podbean.com/e/restoring-ba…

Our COO Dr. Michael Ringel discusses our preparations for the first partial epigenetic reprogramming clinical trials for glaucoma & NAION in this Longevity Technology article. We aim to restore cellular function to combat age-related diseases. Read more:

For over 100 years, advances in treating Type 1 diabetes (T1D) have transformed lives, yet the need for less burdensome solutions remains. With our Cell Pouch bio-hybrid organ we aim to give people their lives back and ease the burden on T1D. Learn more: bit.ly/4aLTohB

Our team has evolved over the last several months – check out our website to learn about our combined expertise and experience which we are leveraging to drive the clinical advancement of our Cell Pouch bio-hybrid organ: bit.ly/42700Dn

The CorVista System was featured in Pulmonary Hypertension News, highlighting new data on its potential to support heart failure diagnosis by measuring elevated PCWP. Learn how this non-invasive, AI-powered technology could help deliver timely, accurate insights at the point of care.

Our CEO, Adrian Lam, joined Tom Salemi on the #DeviceTalksWeekly Podcast to discuss CorVista’s approach to using #AI in #CardiacDiagnostics and life lessons from his career journey. 🎧 Listen here: devicetalks.com/corvista-using…

New data showing #pelareorep’s ability to activate immune responses in patients with #PancreaticCancer will be presented at #ASCO25. Learn more here: bit.ly/42VdW53 #CancerResearch #ImmunoOncology #Oncology

With our Cell Pouch bio-hybrid organ, we aim to establish an environment in the body that supports the long-term survival and function of therapeutic cells. Learn more on our website: bit.ly/41shB9R

On #WorldPHDay we’re shining a light on #PulmonaryHypertension, a serious and often misdiagnosed disease that strains the lungs and heart, impacting lives across all ages. On average it takes 2.5 years from the first doctor's visit to receive an accurate PH diagnosis. We are

The European Respiratory Journal has published compelling evidence that the CorVista System can accurately detect elevated mean pulmonary artery pressure (mPAP) – a hallmark of #PulmonaryHypertension. #PH remains vastly under diagnosed, with patients waiting an average of two

Don't miss our CEO, Jonathan Rigby, and clinical advisor, Dr. Robert Gabbay, discuss the past, present, and future of treating type 1 diabetes as part of Technology Networks' Innovations in BioPharma 2025 online event. Register here: bit.ly/3S6cwP9

We’re thrilled to see our very own Ebrahim Delpassand, M.D. featured in Nature Biotechnology’s latest story on future of #radiopharmaceuticals! RadioMedix is proud to be at the forefront of the latest discoveries in #theranostics. Read the full article: go.nature.com/3H0YLyQ